Associated Papers
Single-center study on clinicopathological and typical molecular pathologic features of metastatic brain tumor.
Kim SH et al.
Journal of Pathology and Translational Medicine, 2023
Establishment and characterization of a new human colon cancer cell line, PUMC-CRC1.
Bian X et al.
Scientific Reports, 2021
Binimetinib, a novel MEK1/2 inhibitor, exerts anti-leukemic effects under inactive status of PI3Kinase/Akt pathway.
Sakakibara K et al.
International Journal of Hematology, 2019
Recombination activity of human recombination-activating gene 2 (RAG2) mutations and correlation with clinical phenotype.
Tirosh I et al.
The Journal of Allergy and Clinical Immunology, 2019
A KRAS wild type mutational status confers a survival advantage in pancreatic ductal adenocarcinoma.
Windon AL et al.
Journal of Gastrointestinal Oncology, 2018
Novel recurrently mutated genes and a prognostic mutation signature in colorectal cancer.
Yu J et al.
Gut, 2015
24951259 (PubMed )
Supplement: gutjnl-2013-306620-s13.pdf
PDX-1: demonstration of oncogenic properties in pancreatic cancer.
Liu SH et al.
Cancer, 2011
[K-RAS gene mutations in patients with non-small cell lung cancer].
Zhang Y et al.
Zhongguo Fei Ai Za Zhi = Chinese Journal of Lung Cancer, 2010
The combined status of ATM and p53 link tumor development with therapeutic response.
Jiang H et al.
Genes & Development, 2009
Molecular alterations in tumors and response to combination chemotherapy with gefitinib for advanced colorectal cancer.
Ogino S et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2005
Select a paper to view details